TOX as a new diagnostic marker for T cell large granular lymphocytic leukaemia

Histopathology. 2024 Mar;84(4):697-701. doi: 10.1111/his.15114. Epub 2023 Dec 12.

Abstract

Aims: T cell large granular lymphocytic leukaemia (T-LGLL) is a rare disorder that may underlie otherwise unexplained cytopenias. The identification of T-LGLL cells in bone marrow biopsies can be a challenge, because a robust immunohistochemistry marker is lacking. The markers currently in use (granzyme B, TIA-1 and CD8) are difficult to interpret or lack specificity. Therefore, we investigated whether immunohistochemistry for thymocyte selection-associated high-mobility group box (TOX), a transcription factor that associates with chronic T cell stimulation, could be a reliable tool for the identification of T-LGLL cells.

Methods and results: In this retrospective study, expression of TOX in CD8+ cells in bone marrow biopsies of T-LGLL patients (n = 38) was investigated and compared to bone marrow of controls with reactive T cell lymphocytosis (n = 10). All biopsies were evaluated for TOX staining within the CD8-positive T cell population. The controls were essentially negative for TOX, whereas all T-LGLL cases were positive (median = 80%, range = 10-100%), even when bone marrow involvement was subtle.

Conclusion: TOX is a highly sensitive marker for the neoplastic cells of T-LGLL and we recommend its use, especially in the diagnostic work-up of patients with unexplained cytopenias.

Keywords: T cell large granular lymphocytic leukaemia; TOX protein; bone marrow; cytopenia; diagnosis; immunohistochemistry.

MeSH terms

  • Bone Marrow / pathology
  • CD8-Positive T-Lymphocytes / pathology
  • Humans
  • Leukemia, Large Granular Lymphocytic* / diagnosis
  • Leukemia, Large Granular Lymphocytic* / metabolism
  • Leukemia, Large Granular Lymphocytic* / pathology
  • Lymphocytosis* / pathology
  • Retrospective Studies

Substances

  • TOX protein, human